AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32655940
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of 1.25 mg (0.05 ml) bevacizumab followed by phacoemulsification, pars plana vitrectomy (PPV) including panretinal photocoagulation (PRP), and trabeculectomy with mitomycin C (MMC)
Trial: 32656160
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of candesartan (16 mg) and amlodipine (10 mg)
Trial: 32656160
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of individual formulations of candesartan (16 mg) and amlodipine (10 mg)
Trial: 32657505
Drug: Sebelipase alfa
RxNorm normalized name: Sebelipase alfa
DrugBank: Sebelipase alfa (DB11563)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sebelipase alfa (1.0 or 3.0 mg/kg every other week) for up to 5 years
Trial: 32658816
Drug: Manic phase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manic phase (before treatment)
Trial: 32658816
Drug: Euthymic phase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euthymic phase (post treatment)
Trial: 32659786
Drug: Glucocorticoids administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucocorticoids administration
Trial: 32660470
Drug: Bronchodilator response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bronchodilator response (BDR) in FEV1
Trial: 32660470
Drug: Limit of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limit of 400 mL in BDR in FEV1
Trial: 32660613
Drug: Metformin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treatment for one year
Trial: 32661003
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg raltegravir twice daily
Trial: 32661186
Drug: Buparlisib in
RxNorm normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buparlisib in combination with temozolomide (stage I)
Trial: 32661186
Drug: Buparlisib in
RxNorm normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buparlisib in combination with temozolomide and radiotherapy (stage II)
Trial: 32661186
Drug: Buparlisib in
RxNorm normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buparlisib in combination with temozolomide and radiotherapy
Trial: 32661752
Drug: 670 nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 670 nm photobiomodulation (PBM) delivered via a retinal laser, 12 sessions over 5 weeks, 90 seconds per treatment at settings of 25, 100 or 200 mW/cm²
Trial: 32662547
Drug: Actionable pharmacogenomic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actionable pharmacogenomic diplotypes/phenotypes for medications including tacrolimus, azathioprine, clopidogrel, warfarin, simvastatin, voriconazole, antidepressants, and proton-pump inhibitors.
Trial: 32662758
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low BMD (<80 mg/cm³)
Trial: 32663093
Drug: Pediatric weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric weight management interventions; details on dosage and duration not available.
Trial: 32664901
Drug: Long-term opioid
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term opioid therapy (LTOT)
Trial: 32664901
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (non-opioid analgesics)
Trial: 32665297
Drug: Neoadjuvant pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant pembrolizumab (200 mg)
Trial: 32665314
Drug: High-normal eGFR
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-normal eGFR (≥103.9 mL/min/1.73 m²)
Trial: 32665314
Drug: Deciles 1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deciles 1, 9, and 10 (eGFR <50.9, 50.9-62.7, and ≥103.9 mL/min/1.73 m²)
Trial: 32665855
Drug: Preoperative fluoropyrimidine
RxNorm normalized name: 5-Fluoropyrimidine-2,4-dione
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Preoperative fluoropyrimidine with radiotherapy (standard treatment)
Trial: 32666050
Drug: Vinblastine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinblastine and nilotinib combination (vinblastine once weekly, nilotinib orally BID for 12 cycles of 28 days)
Trial: 32666871
Drug: SELUTION Sustained-Limus-Release
RxNorm normalized name: omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SELUTION Sustained-Limus-Release Drug-Eluting Balloon
Trial: 32667729
Drug: Renin-angiotensin system
RxNorm normalized name: Renin-angiotensin system inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin-angiotensin system (RAS) drugs
Trial: 32667729
Drug: RAS blocker
RxNorm normalized name: RAS
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RAS blocker monotherapy
Trial: 32667729
Drug: RAS blocker/diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAS blocker/diuretic combo
Trial: 32669223
Drug: Optimal pharmacological
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal pharmacological treatment (OPT) including lipid lowering drugs
Trial: 32669223
Drug: Overall prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall prescription prevalence of OPT
Trial: 32669223
Drug: Time trends
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time trends in prescription prevalence of OPT
Trial: 32669376
Drug: Encorafenib (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encorafenib (450 mg) plus Binimetinib (45 mg)
Trial: 32669548
Drug: HER2 CAR
RxNorm normalized name: RHUMAB HER2
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: HER2 CAR T cells after lymphodepleting chemotherapy, followed by four more CAR T-cell infusions without lymphodepletion.
Trial: 32669548
Drug: Additional CAR
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional CAR T-cell infusions with pembrolizumab.
Trial: 32669548
Drug: 20 months
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 20 months off T-cell infusions.
Trial: 32670103
Drug: Standardized antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized antidepressant therapy
Trial: 32670418
Drug: 15-mg crocin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-mg crocin, twice daily, for 12 weeks
Trial: 32670424
Drug: UGN-101 (mitomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UGN-101 (mitomycin gel)
Trial: 32670599
Drug: 16-week heavy
RxNorm normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16-week heavy shoulder strengthening exercise programme (3 times weekly) targeting scapular and rotator cuff muscles
Trial: 32670812
Drug: Ketogenic diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketogenic diet supplemented with 10 g essential amino acids
Trial: 32673071
Drug: Chemokine Receptor
RxNorm normalized name: Chemokine receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemokine Receptor 2-targeted Molecular Imaging
Trial: 32673265
Drug: Del Nido
RxNorm normalized name: Del Nido Cardioplegia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Del Nido cardioplegia solution (DNS)
Trial: 32673265
Drug: Cardi-Braun blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardi-Braun blood cardioplegia solution
Trial: 32673270
Drug: Peer-led physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer-led physical activity intervention (3-month duration, 6 biweekly video chat sessions, Fitbit Charge 3, weekly feedback)
Trial: 32673385
Drug: Rituximab/chemotherapy (R-Chemo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab/chemotherapy (R-Chemo)
Trial: 32673446
Drug: Fedratinib 500
RxNorm normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fedratinib 500 mg daily for 14 days
Trial: 32674634
Drug: Evolocumab, 480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab, 480 mg every 4 weeks for 6 weeks
Trial: 32676702
Drug: Patients treated
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients treated with metformin and/or statins
Trial: 32676980
Drug: Activities of
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activities of daily living measured by IBM-FRS
Trial: 32677106
Drug: (+)-Epicatechin (EPI)
RxNorm normalized name: epicatechin
DrugBank: Epicatechin (DB12039)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (+)-Epicatechin (EPI) at 75 mg/d for 24 weeks, escalating to 150 mg/d at 12 weeks if no improvement
Trial: 32677968
Drug: Hepatitis-B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis-B vaccine with five different adjuvant formulations
Trial: 32678436
Drug: 6-week blueberry-enriched
RxNorm normalized name: BLUEBERRY
DrugBank: Blueberry (DB10629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-week blueberry-enriched diet (38 g of freeze-dried blueberries daily)
Trial: 32680480
Drug: Ambrisentan 5
RxNorm normalized name: ambrisentan 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan 5 mg once daily for 12 weeks, followed by 12-week dose titration (up to 10 mg)
Trial: 32680541
Drug: Intraovarian injection
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAOVARIAN LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraovarian injection of autologous bone marrow-derived mesenchymal stem cells
Trial: 32681140
Drug: Low anterior
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low anterior resection for rectal cancer
Trial: 32681682
Drug: Lorlatinib 100
RxNorm normalized name: lorlatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib 100 mg once daily (EXP3B subgroup)
Trial: 32681700
Drug: sST2 levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sST2 levels ≥35 ng/mL among survivors
Trial: 32682670
Drug: Ataluren (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ataluren (a read-through agent for premature nonsense codons)
Trial: 32682875
Drug: Sleep medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep medications (including benzodiazepines)
Trial: 32683528
Drug: Microgravity exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microgravity exposure (μg)
Trial: 32683644
Drug: IV tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV tramadol 25 mg
Trial: 32687189
Drug: Saliva Iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saliva Iodine Concentration (SIC) <105 μg/L
Trial: 32687189
Drug: Saliva Iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saliva Iodine Concentration (SIC) >273 μg/L
Trial: 32687629
Drug: Pharmacological interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmacological interventions (weight loss medications, medication switching)
Trial: 32687977
Drug: Rectal location
RxNorm normalized name: Potassium cation
DrugBank: Potassium cation (DB01345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal location
Trial: 32687977
Drug: Logistic regression
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Logistic regression model based on lesion size and rectal location
Trial: 32687977
Drug: NNT for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNT for rectal SMIC of 4 cm or more
Trial: 32690535
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (patients who refused ASV or stopped treatment early)
Trial: 32690731
Drug: Serological HPA-1a
RxNorm normalized name: Peginterferon Beta-1A
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Serological HPA-1a typing and luminex-based multiplex assay for detection of anti-HPA-1a antibodies.
Trial: 32690735
Drug: Classic permissive
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classic permissive strategy of antibiotic prophylaxis and treatment
Trial: 32690797
Drug: bimagrumab 10
RxNorm normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bimagrumab 10 mg/kg IV every 4 weeks up to 2 years (104 weeks)
Trial: 32691242
Drug: Idarucizumab (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarucizumab (2.5 + 2.5 g, intravenous) administered 2 hours after the last administration of dabigatran etexilate (220 mg b.i.d., oral)
Trial: 32691242
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate (220 mg b.i.d., oral) alone
Trial: 32692367
Drug: 3.5 g
RxNorm normalized name: Calcium 760 MG/3.5 GM Oral Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 g GOS
Trial: 32692367
Drug: 7 g
RxNorm normalized name: Vaporizer 1.7 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 g GOS
Trial: 35015879
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g GOS
Trial: 32692367
Drug: 7 g
RxNorm normalized name: Vaporizer 1.7 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 g GOS with 93 mg AA
Trial: 32692450
Drug: Palbociclib (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib (125 mg daily for days 1-21 of 28-day cycles)
Trial: 34496014
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg IV every 3 weeks
Trial: 32695577
Drug: Korean medicine
RxNorm normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean medicine treatments for LBP
Trial: 32695923
Drug: Educational programme
RxNorm normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational programme for blood management (non-drug intervention) in group A
Trial: 32695923
Drug: Systematic correction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic correction of perioperative iron, vitamin deficiencies, and anaemia (drug intervention) in group B
Trial: 32695954
Drug: Home-based rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based rehabilitation program (twice a week for 3 months)
Trial: 32696319
Drug: TTC-352 (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTC-352 (180 mg twice a day)
Trial: 32696441
Drug: Darunavir 600
RxNorm normalized name: darunavir 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir 600 mg q24h
Trial: 32696441
Drug: Darunavir 400
RxNorm normalized name: darunavir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir 400 mg q24h
Trial: 32696441
Drug: Darunavir 800
RxNorm normalized name: darunavir 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir 800 mg q24h for 5 days followed by 2 days of treatment interruption
Trial: 32696441
Drug: Current treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current treatment guidelines (darunavir 800 mg q24h or 600 mg q12h)
Trial: 32696663
Drug: Antithrombotic management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic management focusing on stroke/systemic embolism prevention, uptake of new oral anticoagulants
Trial: 32696697
Drug: Enriched marine
RxNorm normalized name: marine non-gelling gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enriched marine oil supplement (3 escalating doses, 5-day oral administration)
Trial: 32698195
Drug: Zanubrutinib 160
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanubrutinib 160 mg orally twice daily (n = 50)
Trial: 32698195
Drug: Zanubrutinib 320
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanubrutinib 320 mg orally once daily (n = 23)
Trial: 32698532
Drug: Papaya Mosaic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papaya Mosaic Virus adjuvant (30 to 240 µg) combined with trivalent influenza vaccine
Trial: 32698642
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of cefazolin
Trial: 32698642
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of cefuroxime
Trial: 34859113
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of cefazolin
Trial: 32698642
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of cefazolin (knee)
Trial: 32698642
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of cefuroxime (knee)
Trial: 32698642
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of cefazolin (knee)
Trial: 32699021
Drug: Vaginal brachytherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal brachytherapy or no adjuvant treatment
Trial: 32699580
Drug: Fibrin sealant
RxNorm normalized name: FIBRIN SEALANT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin sealant (FS) applied circumferentially after anastomosis (2.5 mL of porcine FS)
Trial: 32699642
Drug: Executive Functioning
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Executive Functioning for Enhancing Community-based Treatment for ASD (EFFECT for ASD)
Trial: 32699643
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (TXA) 1 g at the start and end of surgery
Trial: 32699643
Drug: Oral rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rosuvastatin 40 mg before and 20 mg daily for 30 days after surgery
Trial: 32699645
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavioral treatment for gambling
Trial: 32699926
Drug: Breast-Conserving Therapy
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast-Conserving Therapy (BCT) with whole-breast radiation
Trial: 32700065
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg AG-221 oral dose
Trial: 32700765
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with hormone receptor (HR) positive metastases
Trial: 32701541
Drug: Epidural steroid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural steroid injections (ESI) for leg pain
Trial: 34880117
Drug: Sacroiliac joint
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacroiliac joint (SIJ) injections
Trial: 32702156
Drug: Peri-interventional dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peri-interventional dual antiplatelet therapy (DAPT)
Trial: 32702156
Drug: Concurrent surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent surgery
Trial: 32703167
Drug: Cochlear implant
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear implant rehabilitation
Trial: 32704173
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg daily and Lenalidomide 25 mg daily
Trial: 32704173
Drug: Everolimus and
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus and Lenalidomide combination
Trial: 32709218
Drug: Early-stage ADPKD
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early-stage ADPKD treatment options (specific treatment details not provided)
Trial: 32709235
Drug: Pre- and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre- and post-bronchodilator spirometry tests
Trial: 32710011
Drug: Antibody-radionuclide conjugate
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibody-radionuclide conjugate targeting CD45
Trial: 32711479
Drug: Matched control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched control group with normal kidney function (estimated glomerular filtration rate ≥ 60 ml/min/1.73m²)